• Explore /
  • Poster
  • / Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

Abstract Video & Slides Poster

Authors

null

Hun Ju Lee

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Hun Ju Lee , Michael Y. Choi , Tanya Siddiqi , Jacqueline Claudia Barrientos , William G. Wierda , Iris Isufi , Joseph M. Tuscano , Nicole Lamanna , Suki Subbiah , Jean Louise Koff , Lori Ann Leslie , Alec Goldenberg , Gina G. Chung , James Bradley Breitmeyer , Frank J. Hsu , Michael Wang , Catriona Jamieson , Thomas J. Kipps

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03088878

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7556)

DOI

10.1200/JCO.2021.39.15_suppl.7556

Abstract #

7556

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Hun Ju Lee

First Author: Hun Ju Lee

Poster

2019 ASCO Annual Meeting

Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

First Author: Michael Y. Choi

First Author: Pier Luigi Zinzani